Rezolute, Inc. — Form 8-K
Filed October 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 71/100
What the filing says
Rezolute announced full enrollment of its Phase 3 upLIFT registrational study of ersodetug in tumor hyperinsulinism on October 14, 2026, with 16 participants. The primary endpoint requires ≥56% response rate (95% CI lower bound ≥30%) for statistical significance; preliminary data from first 8 participants showed 7 of 8 met responder criteria (87.5%), with each achieving complete IV glucose discontinuation and no drug-related safety issues. Topline results expected mid-December 2026.
Why this rating
Late-stage clinical milestone for ultra-rare disease company; 16-patient study size material relative to $259M market cap; early efficacy signal (7/8 responders) is encouraging but final results remain pending. Regulatory approval not guaranteed.
Tradability signal
NO TRADE
No trade: positive news with only -1.3% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.15% over 4 hrs, n=240). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $4.28 ▲ 1.42% | at our read · unknown $4.22 | +10 min · unknown $4.21 ▼ 0.12% | +30 min · unknown $4.30 ▲ 1.90% | +1 hr · unknown $4.14 ▼ 1.90% | +4 hrs · unknown $4.01 ▼ 4.86% |
The stock had already moved -1.40% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.